ThromboGenics strengthens leadership team

8 November 2017

Belgian biotech firm ThromboGenics (Euronext Brussels: THR), which is focussed on developing novel medicines for back of the eye diseases and focused on diabetic eye disease, today announced it has strengthened its senior leadership team, attracting former executives from Allergan and Novartis.

ThromboGenics has appointed Susan Schneider as chief medical officer, and Vinciane Vangeersdaele as chief commercial officer. Both will be members of the company’s executive team reporting to ThromboGenics’ chief executive Patrik De Haes, and they will operate from the company’s offices in Leuven, Belgium and Iselin, New Jersey, USA.

Dr Schneider brings nearly 15 years of experience in clinical drug development to ThromboGenics. Prior to joining ThromboGenics, she was, most recently, vice president and therapeutic area head of Retina & Glaucoma at Allergan. At ThromboGenics, Dr Schneider will be responsible for the development and execution of the company’s global clinical and medical programs that are focused on its industry-leading pipeline of drug candidates targeting diabetic eye disease.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK